Abstract #3207

METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) for castration-resistant prostate cancer: prediction of clinical course, and identification of oligo-progressive lesions as targets for loco-regional ablative therapy.

Soichiro Yoshida¹, Taro Takahara^2,3, Chikako Ishii³, Thomas C Kwee⁴, Keiko Nakagawa⁵, Kazuma Toda⁵, Yuki Arita³, Toshiki Kijima¹, Minato Yokoyama¹, Junichiro Ishioka¹, Yoh Matsuoka¹, Kazutaka Saito¹, Ryoichi Yoshimura⁵, Kazunori Kihara¹, and Yasuhisa Fujii¹

¹Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan, ²Biomedical Engineering, Tokai University School of Engineering, Kanagawa, Japan, ³Radiology, AIC Yaesu Clinic, Tokyo, Japan, ⁴Radiology, UMC Groningen, Groningen, Netherlands, ⁵Radiation Therapeutics and Oncology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

Whole-body diffusion-weighted MRI is a new-generation imaging tool for detecting prostate cancer. The extent of bone metastasis and the presence of visceral metastasis on whole-body diffusion-weighted MRI according to METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) were associated with a lower cancer-specific survival in castration-resistant prostate cancer. Furthermore, whole-body diffusion-weighted MRI facilitates identification of oligo-progressive lesions, which can be targets for loco-regional radiotherapy. MET-RADS-P score of whole-body diffusion-weighted MRI can be an imaging biomarker for castration-resistant prostate cancer in predicting clinical course, and identifying oligo-progressive lesions as targets for loco-regional ablative therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here